Startup | December 05, 2025
Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Here's a development that aims to keep your blood pressure in check. Literally!
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Patients can now get the starting 2.5 mg dose for $299 per month
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Subscribe To Our Newsletter & Stay Updated
